BIO Bound

  • by: |
  • 06/22/2014

My bags are packed. I’m ready to go.

As many of us head out to San Diego for BIO, it’s important to put the gathering in the proper perspective. It’s not just about business. It’s not just about networking. It’s about advancing the public health. It’s about protecting and advancing innovation.

Attached is a letter that Pfizer honcho Ian Read just sent to Representative Fred Upton. Mr. Upton, as you are likely aware, is the Chairman of the House Committee on Energy & Commerce and has been leading a series of hearings on 21st Century Cures.

Ian also attached a more complete thought piece on a series of innovation priorities. Innovation? Read all about.

While at BIO I’ll be participating in two panels.

The first: Will Government and Payor Policies Encourage Innovation and Create Incentives for the Continued Development of Abuse Deterrent Formulations and Improvements to Existing Technologies in the Regulatory Review and Approval Track?


Peter Pitts, Moderator, President and co-founder, Center for Medicine in the Public Interest

Douglas Throckmorton, MD, Deputy Director of Regulatory Programs, FDA’s Center for Drug Evaluation and Research

Richard C. Dart, MD, PhD, Director of the Rocky Mountain Poison and Drug Center

J. David Haddox, DDS, MD, Vice President of Health Policy for Purdue Pharma, L.P.

WHERE: San Diego Convention Center Room 31 B

WHEN:   Tuesday, June 24 2014, 9:00 am –10:00 am

The second: Thriving Again in 2014: Preparing for Success, Not Just Survival at FDA Advisory Committee Meetings


David Schull, president of Russo Partners

Penny Daniels, strategic communications consultant at 3D Communications

Craig Audet, Ph.D., senior vice president, operations and head of global regulatory affairs with Arena Pharmaceuticals, Inc.

Peter Pitts, president and co-founder of the Center for Medicine in the Public Interest and former FDA associate commissioner of external affairs

Silvia Taylor, senior vice president, investor relations, public relations, and corporate communications at Sucampo Pharmaceuticals, Inc.

WHERE: San Diego Convention Center Room 31B

WHEN:   Tuesday, June 24 2014, 3:00PM – 4:00PM

In addition, the Center for Medicine in the Public Interest will have a booth. It’s #5642. And we’ll be talking about innovation. 

Hope to see you there.


Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
Better Health
Biotech Blog
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
Envisioning 2.0
FDA Law Blog
Fierce Pharma
Fresh Air Fund
Furious Seasons
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
In the Pipeline
In Vivo
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
More than Medicine
National Review
Neuroethics & Law
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmacology Corner
Pharmaceutical Business Review
Piper Report
Prescription for a Cure
Public Plan Facts
Real Clear Politics
Shark Report
Shearlings Got Plowed
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog